Issue link: http://www.e-digitaleditions.com/i/686898
Inhalation JUNE 2016 7 multidisciplinary scientific network that will coordinate and enhance research and development with the aim of improving efficiency, safety and convenience of inhaled medi- cines, as well as to reduce costs of pul- monary drug delivery. Through the combined expertise of specialists in the fields of particle engineering and formulation devel- opment, inhaler engineering and design, integrated computer simula- tions, advanced imaging, patient monitoring and delivery verification, as well as toxicity, risk assessment and regulation, Siminhale aims at mak- ing a new generation of advanced inhaled pharmaceuticals (formula- tions and devices) available to the public as quickly and cost effectively as possible. As such, Siminhale is actively pro- moting the welfare of patients and contributing to European scientific and technological excellence, society and the economy. Its mission is to enable breakthrough scientific and technological developments leading to new concepts and products and thereby contribute to strengthening Europe's research and innovation capacities. Organized into five work packages, Siminhale intends to inte- grate fragmented and compartmen- talized knowledge in the following areas. Anticipated benefits and impact Siminhale will integrate scientific knowledge across disciplines and geo- graphical boundaries in order to accelerate progress and promote syn- ergies. It will enable the flow of infor- mation among research groups that are separated by distance, area of expertise or level of experience, thus maximizing the effective use of all available European resources in the field of inhaled medicines. It will dis- seminate state-of-the-art information across Europe and will bring know- how from across Europe into the mainstream. Siminhale will aim, in particular, at enhancing the interac- tion between academic research insti- tutions on one hand and industrial stakeholders and regulatory agencies on the other. The benefits of the Action will be of scientific and technological, eco- nomical and, of course, societal character. Making a new generation of advanced inhaled pharmaceuti- cals available to patients rapidly and economically will have enormous social benefits. It will also have sig- nificant economic benefits because it will advance pharmaceuticals with higher effectiveness and fewer side effects, thus reducing healthcare costs in the long run. It will also help sustain innovation in the industry of inhaled pharmaceuticals and inhaler devices. A list of activities is shown in Table 1. The Breath of Life Society A scientific network of early career investigators has been established under the name the "Breath of Life Society." The society will be able to meet separately during Siminhale